Status and thoughts of Chinese patent medicines seeking approval in the US market / 中国结合医学杂志
Chinese journal of integrative medicine
;
(12): 403-408, 2014.
Article
in English
| WPRIM
| ID: wpr-262645
ABSTRACT
Veregen™ and Fulyzaq are the first two botanical drug products that were approved by the Food and Drug Administration (FDA) to market in the US in recent years. Additional herbal medicines, including Compound Danshen Dripping Pills, Fuzheng Huayu Tablets, Xuezhikang Capsule, Guizhi Fuling Capsule, Kanglaite Capsule and Kanglaite Injection, have filed the investigational new drug (IND) application to the FDA and are in phase II or phase III clinical development. In order to gain better understanding of the process of botanical drug approval in the US, this article examines the aforementioned drugs by looking at their composition, indication, prior clinical experience and clinical development process, and summarizes key features that enabled IND filing and marketing approval by the FDA.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
United States
/
United States Food and Drug Administration
/
Drugs, Chinese Herbal
/
China
/
Drug Approval
/
Therapeutic Uses
/
Nonprescription Drugs
Limits:
Humans
Country/Region as subject:
North America
/
Asia
Language:
English
Journal:
Chinese journal of integrative medicine
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS